<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Infect Dis</journal-id><journal-title>BMC Infectious Diseases</journal-title><issn pub-type="epub">1471-2334</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15357874</article-id><article-id pub-id-type="pmc">PMC518965</article-id><article-id pub-id-type="publisher-id">1471-2334-4-34</article-id><article-id pub-id-type="doi">10.1186/1471-2334-4-34</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A human <italic>in vitro </italic>model system for investigating genome-wide host responses to SARS coronavirus infection</article-title></title-group><contrib-group><contrib id="A1" equal-contrib="yes" contrib-type="author"><name><surname>Ng</surname><given-names>Lisa FP</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>ngfp@gis.a-star.edu.sg</email></contrib><contrib id="A2" equal-contrib="yes" contrib-type="author"><name><surname>Hibberd</surname><given-names>Martin L</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>hibberdml@gis.a-star.edu.sg</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Ooi</surname><given-names>Eng-Eong</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>gptoee@sgh.com.sg</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Tang</surname><given-names>Kin-Fai</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>gpttkf@sg.com.sg</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Neo</surname><given-names>Soek-Ying</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>neosy3@gis.a-star.edu.sg</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Tan</surname><given-names>Jenny</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>tanhh@gis.a-star.edu.sg</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Krishna Murthy</surname><given-names>Karuturi R</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>karuturikm@gis.a-star.edu.sg</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Vega</surname><given-names>Vinsensius B</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>vegav@gis.a-star.edu.sg</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Chia</surname><given-names>Jer-Ming</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jerm@gmx.net</email></contrib><contrib id="A10" contrib-type="author"><name><surname>Liu</surname><given-names>Edison T</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>liue@gis.a-star.edu.sg</email></contrib><contrib id="A11" corresp="yes" contrib-type="author"><name><surname>Ren</surname><given-names>Ee-Chee</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>renec@gis.a-star.edu.sg</email></contrib></contrib-group><aff id="I1"><label>1</label>Genome Institute of Singapore, 60 Biopolis Street, Genome, #02-01, Singapore 138672</aff><aff id="I2"><label>2</label>Department of Microbiology, Faculty of Medicine, National University of Singapore, Block MD4, 5 Science Drive 2, Singapore 117597</aff><aff id="I3"><label>3</label>Enviromental Health Institute, National Environment Agency, 41 Science Park Road, #03-24/28, The Gemini, Singapore Science Park II, Singapore 117610</aff><pub-date pub-type="collection"><year>2004</year></pub-date><pub-date pub-type="epub"><day>9</day><month>9</month><year>2004</year></pub-date><volume>4</volume><fpage>34</fpage><lpage>34</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2334/4/34"/><history><date date-type="received"><day>11</day><month>6</month><year>2004</year></date><date date-type="accepted"><day>9</day><month>9</month><year>2004</year></date></history><copyright-statement>Copyright &#x000a9; 2004 Ng et al; licensee BioMed Central Ltd.</copyright-statement><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license><abstract><sec><title>Background</title><p>The molecular basis of severe acute respiratory syndrome (SARS) coronavirus (CoV) induced pathology is still largely unclear. Many SARS patients suffer respiratory distress brought on by interstitial infiltration and frequently show peripheral blood lymphopenia and occasional leucopenia. One possible cause of this could be interstitial inflammation, following a localized host response. In this study, we therefore examine the immune response of SARS-CoV in human peripheral blood mononuclear cells (PBMCs) over the first 24 hours.</p></sec><sec sec-type="methods"><title>Methods</title><p>PBMCs from normal healthy donors were inoculated <italic>in vitro </italic>with SARS-CoV and the viral replication kinetics was studied by real-time quantitative assays. SARS-CoV specific gene expression changes were examined by high-density oligonucleotide array analysis.</p></sec><sec><title>Results</title><p>We observed that SARS-CoV was capable of infecting and replicating in PBMCs and the kinetics of viral replication was variable among the donors. SARS-CoV antibody binding assays indicated that SARS specific antibodies inhibited SARS-CoV viral replication. Array data showed monocyte-macrophage cell activation, coagulation pathway upregulation and cytokine production together with lung trafficking chemokines such as IL8 and IL17, possibly activated through the TLR9 signaling pathway; that mimicked clinical features of the disease.</p></sec><sec><title>Conclusions</title><p>The identification of human blood mononuclear cells as a direct target of SARS-CoV in the model system described here provides a new insight into disease pathology and a tool for investigating the host response and mechanisms of pathogenesis.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>The causative agent for SARS has been identified as a novel coronavirus [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref>] with genome sequence revealing no strong homology to existing known coronaviruses [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B6">6</xref>]. Coronaviruses belong to the family of enveloped viruses called <italic>Coronaviridae</italic>, and have the largest known single-stranded viral RNA genomes (27 to 32 kb). Coronaviruses, have both "early" and "late" phases of gene expression. Regulatory proteins are synthesized as "early" non-structural proteins, while the structural proteins are synthesized as "late" proteins. "Late" structural proteins are usually required in greater amounts thus, there is a necessity to regulate the expression of the viral genes quantitatively. After the viral entry via endocytosis or through specific receptors, the 5'-end of the viral genome is translated directly giving rise to twenty-three viral proteins, including the RNA dependent RNA polymerase (RdRp), and other functional products involved in transcription, replication, viral assembly and cell death. Coronaviruses can be classified into species and three major antigenic groups based on, serology, natural hosts, monoclonal antibody recognition and nucleotide sequencing [<xref ref-type="bibr" rid="B7">7</xref>]. Most coronaviruses have restricted host ranges as they infect only one host species or, at most, a few related species, they are an important group of animal pathogens. Group one (I) includes human coronavirus 229E (HCoV), porcine transmissible gastro-enteritis virus (TGEV) and feline enteric coronavirus (FECoV). Group two (II) includes bovine coronavirus (BCoV), murine hepatitis virus (MHV), and HCoV-OC43; and Group three (III) includes avian infectious bronchitis virus (IBV) [<xref ref-type="bibr" rid="B7">7</xref>]. Some coronaviruses like HCoV have restricted tissue tropism, including macrophages [<xref ref-type="bibr" rid="B8">8</xref>], although most strains that infect humans cause only mild respiratory infections.</p><p>However, SARS has rapidly caused a world-wide problem. The earliest known cases of SARS was reported in Guandong Province, China in November 2002, becoming more widespread by March 2003, when it was introduced to Canada, Singapore, Taiwan and Vietnam via Hong Kong. The largest number of infected patients has been in China with a worldwide incidence totalling more than 8,400 by July 2003. Infection by the virus induces high morbidity and mortality, the latter being estimated at 15% by the World Health Organisation. SARS is characterized by high fever, non-productive cough or dyspnea and in many cases may progress to generalized, interstitial infiltrates in the lung, thus needing intubation and mechanical ventilation [<xref ref-type="bibr" rid="B2">2</xref>]. The characteristic compression of alveolar sacs seen in atypical pneumonia is largely due to fluid build up outside the alveoli. One possible cause of this could be interstitial inflammation, following a localised host response. To date, the details of the host response to SARS-CoV infection is still largely unknown and consequently the most appropriate treatment regime remains to be established. Typically a pro-inflammatory cytokine profile (up regulated TNF&#x003b1;, Il1, IL6 and IFNs) is seen in viral infections such as influenza [<xref ref-type="bibr" rid="B9">9</xref>], together with perhaps limited amounts of IL8 and other chemokines [<xref ref-type="bibr" rid="B10">10</xref>] that may depend on which cell type is infected [<xref ref-type="bibr" rid="B11">11</xref>]. In experimental systems the immediate innate immune response has been shown to be directed by the monocyte-macrophage-dendritic lineage to a range of different organisms [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>] and consists of a core set of pathways common to all, together with pathogen specific pathways. This data points to critical time points in the response, with the first 12 hours representing primary events while longer periods the consequence of this activity and a secondary (perhaps larger) cascade of responses.</p><p>We postulated that the pulmonary damage in SARS may not be a direct effect of the virus on the alveoli, but represents a secondary effect of cytokines or other factors proximal to but not from the lung tissue mediated by the host either as the primary or secondary response [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B14">14</xref>]. In this study, we have addressed this question by developing a human <italic>in vitro </italic>model system that will in the future allow detailed investigations of the host response to be made.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Cell culture and virus infection</title><p>PBMCs were obtained by Ficoll-Hypaque separation of whole blood. 2 &#x000d7; 10<sup>5 </sup>PBMCs were seeded into each well of a 24-well culture plate, 0.5 ml of complete RPMI-1640 (Life Technologies-Invitrogen, USA) added to each and cultured overnight at 37&#x000b0;C (5% CO<sub>2</sub>). A seed stock of SARS-CoV (strain SIN 2774) passaged in Vero E6 cells was used for infection. Vero E6 culture supernatants were added to each well in 50 &#x003bc;l volume at a concentration of 0.1 or 0.01 MOI (based on plaque forming units) and a control plate (media only). Each culture was set up in duplicate. After 4 hours of incubation, one set of the duplicate wells of the control plate and a 4 hours incubation plate were harvested while the rest received 0.5 ml media top-up and incubated for a further 2, 4, 6 and 8 days.</p></sec><sec><title>Cell harvest and RNA isolation</title><p>Harvesting was performed by gently flushing the wells with a Pasteur pipette to removed non-adherent cells, followed by a rinse of 1 ml RPMI. The rinsed fraction was pooled with the first harvest aliquot and spun at 1500 rpm. The cell pellet was washed twice with 2 ml RPMI to remove virus in the supernatant. 1.5 ml Trizol (Invitrogen, USA) was then added to the adherent cell fraction as well as the non-adherent cell fraction to lyse cells and stabilize the RNA. Extraction of total RNA was then performed following manufacturer's protocol and the resultant RNA dissolved in 40 &#x003bc;l water.</p></sec><sec><title>Real-time quantitative polymerase chain reaction (PCR)</title><p>The amount of SARS-CoV in each cell fraction was measured by real-time quantitative PCR assay. 2 &#x003bc;l of RNA was reverse transcribed and amplified in 20 &#x003bc;l using 0.9 &#x003bc;M each of forward (5'-GGTTGGGAT TATCCAAAATGTGA-3') and reverse (5'-AGAACAAGAGAGGCCATTATCCTAAG-3') primers, and 0.25 &#x003bc;M of TaqMan<sup>&#x000ae; </sup>MGB probe: 5'-(6-FAM)AGAGCCATGCCTAACAT(NFQ)-3') in a one step PCR using master mix from Applied Biosystems (USA) according to manufacturers' recommendations. Reactions were performed using an ABI PRISM 7900 sequence detection system (48&#x000b0;C for 30 min, followed by 95&#x000b0;C for 10 min and 40 cycles of 95&#x000b0;C for 15 sec and 60&#x000b0;C for 1 min) and quantitation achieved using standard curves generated from <italic>in vitro </italic>transcribed RNA.</p></sec><sec><title>High density oligonucleotide array hybridization</title><p>At each time point (4 hours, 8 hours, 12 hours, 24 hours), 5 &#x000d7; 10<sup>7 </sup>cells of mock-infected and infected cells were harvested and lysed using Trizol (Invitrogen, USA). Total RNA was isolated according to the manufacturer's recommendation. Quality of the total RNA was judged from the ratio between 28S and 18S RNA after agarose gel electrophoresis. 20 &#x003bc;g of total RNA was labeled with Cy-3 or Cy-5 using the Superscript II reverse-transcription kit (Invitrogen, USA) and hybridization was carried out overnight (16 hours) at 42&#x000b0;C on high-density oligonucleotide arrays (~19,200 gene features, Compugen) using universal human reference (Stratagene, USA) as a reference. Hybridized arrays were scanned at 5 &#x003bc;m resolution on a GenePix 4000A scanner (Axon Instruments) with variable photo-multiplier tube voltage to obtain maximal signal intensities, and the resulting images were analyzed via GenePix Pro v4.0 (Axon Instruments) as described in the manual.</p></sec><sec><title>Microarray data analysis</title><p>Raw data were analyzed on GenePix analysis software version 4.0 (Axon Instruments) and uploaded to a relational database. The logarithmic expression ratio for a spot on each array was normalized by subtracting the median logarithmic ratio for the same array. Data were filtered to exclude spots with a size of less than 25 &#x003bc;m and any poor quality or missing spots. Since the correlation of the overall data from reciprocal labeling was good, values obtained from reciprocal labeling experiments were averaged. In addition, the data were distilled to the set of gene features that were present at all 4 time points in both the viral infected samples and the negative controls. The results were represented as the logarithmic ratio of gene expression between the viral infected samples and their corresponding negative controls at the various time points. Application of these filters resulted in the inclusion of ~12,900 of the total ~19,200 gene features in subsequent analyses.</p><p>To discover patterns of gene expression, the values associated with each gene feature <italic>f </italic>were translated so that their means were zero. Similar genes, whose translated gene-features exhibited same induction-repression pattern, were grouped together. Genes <italic>g</italic><sub><italic>i</italic></sub>, <italic>g</italic><sub><italic>j </italic></sub>were said to be similar if they satisfied the following condition:</p><p><inline-graphic xlink:href="1471-2334-4-34-i1.gif"/>, where <italic>U</italic>(<italic>x</italic>) = 1 if <italic>x </italic>&#x0003e; 0, <italic>U </italic>(<italic>x</italic>) = 0 otherwise,</p><p>where <italic>g</italic><sub><italic>it </italic></sub>and <italic>g</italic><sub><italic>jt </italic></sub>denote the translated values of gene features <italic>g</italic><sub><italic>i</italic></sub>, <italic>g</italic><sub><italic>j </italic></sub>at time <italic>t </italic>respectively; and <italic>N </italic>is the number of time points for which the expression of a gene was observed. Similar genes, based on the above criteria, are grouped together. Within each group, the genes were ordered in the descending order of their expression range (defined as the difference between the maximum and minimum ratios of gene expression). This algorithm is a special case of the <italic>Friendly Neighbor </italic>algorithm currently under development. The final plots were generated using the original expression ratios while preserving the clustering and ordering discovered by the above algorithm. To determine whether a gene observed to be responsive could appear merely by chance, 100,000 expression profiles were generated by randomly sampling the expression ratios from the entire dataset with replacement. The <italic>P </italic>value of a gene is the fraction of the random profiles whose logarithmic expression range is as good as, or better than that of the selected gene.</p></sec></sec><sec><title>Results and Discussion</title><sec><title>Kinetics of SARS-CoV replication</title><p>We obtained PBMCs from 6 healthy volunteers by Ficoll-Hypaque separation of whole blood. Of the 6 donor PBMCs tested, all were able to support SARS-CoV replication when infected with multiplicity of infection (MOI) of 0.1. The first sampling, taken from cells infected for 4 hours, showed an average copy number of 32 &#x000d7; 10<sup>3 </sup>(Fig. <xref ref-type="fig" rid="F1">1A</xref>) and represents the initial inoculum level. Over the course of the next 8 days, there was a steady rise in viral load, reaching as high as 480 &#x000d7; 10<sup>3 </sup>copies per well in one donor, which could only be explained by active replication of the SARS-CoV intracellularly. This work is supported by recent <italic>in vivo </italic>evidence suggesting that SARS-CoV may have infected and replicated within PBMCs of SARS patients [<xref ref-type="bibr" rid="B15">15</xref>] and cells from humans and animals [<xref ref-type="bibr" rid="B16">16</xref>]. An indication of the PBMCs lineage involvement was provided by repeating the experiment using the monocyte-macrophage cell line THP-1 [<xref ref-type="bibr" rid="B17">17</xref>], in which viral replication was similar to the primary cell culture over the first 4 days (Fig. <xref ref-type="fig" rid="F1">1B</xref>). In the primary cultures, the non-adherent cell fraction which comprises mainly lymphocytes and granulocytes showed dramatically less viral replication in our assay as did all cells infected at MOI of 0.01 (Fig. <xref ref-type="fig" rid="F1">1A</xref>).</p><p>The kinetics of viral replication was variable among the 6 donors (Fig. <xref ref-type="fig" rid="F1">1C</xref>). There was a lag phase of 2 days in the case of donors a, c and e; and 4 days for donors b, d and f before any significant increase could be detected. The viral replication generally peaked at either day 4 or day 6. The exception was donor b, in which the virus seemed to replicate at a much slower pace compared to the other 5 donor samples. Equally interesting was the different levels of virus attained. Donor d seems to stand out from the rest, reaching a peak of 480 &#x000d7; 10<sup>3 </sup>copies per well which is 4 times more than that attained by donor e, with 120 &#x000d7; 10<sup>3 </sup>copies per well. Such variation strongly suggests that there is an underlying host-pathogen interaction influencing the kinetics of SARS-CoV replication efficiency. These <italic>in vitro </italic>observations may reflect the wide range of patient outcomes after SARS-CoV infection [<xref ref-type="bibr" rid="B18">18</xref>].</p><p>Antibody blocking experiments were also performed in which SARS-CoV was pre-incubated with convalescent patient sera for 30 minutes before introduction to the PBMCs and after a 4 day incubation period, the adherent cell fraction was harvested and assayed for SARS-CoV viral titer. Results clearly showed that even at high dilution, convalescent sera inhibited SARS viral replication (data not shown), presumably by blocking viral entry. This supports other reports indicating that SARS-CoV is not endocytosed through antibody mediated mechanisms and confirms a protective role for antibodies elicited either by the infection or through immunization [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref>].</p></sec><sec><title>SARS-CoV specific gene expression changes</title><p>To further elucidate the molecular processes of SARS-CoV infection, PBMCs from 3 healthy individuals were infected separately <italic>in vitro </italic>with SARS-CoV (0.1 MOI) and harvested at 4 hours, 8 hours, 12 hours and 24 hours time intervals post-infection. As controls, uninfected aliquots of the same PBMCs were also harvested at the corresponding time points. Total RNA extracted from the PBMCs of the 3 individuals were pooled, labeled and hybridized to human oligonucleotide arrays consisting of ~19,200 gene features. Reciprocal dye swap replicate hybridizations were performed to minimize technical noise. Analysis of variance in expression levels for each gene across all the time points indicated the ~1200 genes which showed the largest variability (Fig. <xref ref-type="fig" rid="F2">2A</xref> and <xref ref-type="fig" rid="F2">2B</xref>).</p><p>In order to focus the analysis, we queried the entire data set for genes related to the immune response by keyword searches on their gene ontology descriptions with the aim of describing the specific host-pathogen interaction. In common with other studies of respiratory pathogens [<xref ref-type="bibr" rid="B9">9</xref>-<xref ref-type="bibr" rid="B13">13</xref>], our data points towards two critical time points in the response, with the first 12 hours representing a primary pro-inflammatory cytokine profile while longer periods represent the consequence of this activity and a secondary cascade of responses [<xref ref-type="bibr" rid="B9">9</xref>-<xref ref-type="bibr" rid="B13">13</xref>]. We observed that within the first 12 hours of SARS-CoV infection, evidence of this monocyte-macrophage activation was seen, indicated by enhanced expression of CD14, TLR9 plus NFK&#x003b2;1 and GATA signaling (Fig. <xref ref-type="fig" rid="F2">2C</xref> and Table <xref ref-type="table" rid="T1">1</xref>). In addition, the MRC2 endocytotic receptor was upregulated as was the complement pathway (C1q, C6). Taken together, these data suggest an early activation of the innate immunity pathway. This activation was accompanied by an unusual cytokine transcriptional profile (Fig. <xref ref-type="fig" rid="F2">2C</xref> and Table <xref ref-type="table" rid="T1">1</xref>). While IL1&#x003b2; (up regulated for the first 12 hours) would be expected following macrophage activation [<xref ref-type="bibr" rid="B21">21</xref>], TNF&#x003b1;, IFN&#x003b3; and IL6 were noted by their surprisingly low level of expression. This is in spite of the presence of elevated IL19 which is thought to enhance their up regulation [<xref ref-type="bibr" rid="B22">22</xref>]. In some clinical investigation, concentrations of TNF and IL 6 measured during active disease were found to be relatively low [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref>], reflecting our findings. This paper did not report on IFN levels, however, we found them to be low (Supplementary figure [see <xref ref-type="supplementary-material" rid="S1">Additional file 1</xref>]). This is of particular interest as IFNs have been shown to have significant anti-SARS-CoV effects [<xref ref-type="bibr" rid="B25">25</xref>]. Such effects suggest that alteration of the IFN response and perhaps other immune modulators might provide opportunity for novel treatment and management regimes for SARS patients to be developed.</p><p>A number of CC chemokines (CCL4, CCL20, CCL22, CCL25, CCL27) and their receptors (CCR4 and CCR7) were highly expressed in response to the infection (Fig. <xref ref-type="fig" rid="F2">2C</xref> and Table <xref ref-type="table" rid="T1">1</xref>), indicating a rapid mobilization and increased trafficking, in particular of the monocyte-macrophage lineage very early on in the infection [<xref ref-type="bibr" rid="B26">26</xref>]. CXC chemokines (CXCL9, CXCL12) were also highly expressed suggesting significant increase in neutrophil homing as well. These are likely to be lung directed as IL8 and IL17 were also highly expressed [<xref ref-type="bibr" rid="B27">27</xref>-<xref ref-type="bibr" rid="B32">32</xref>]. Specific trafficking of these cells to the lung may account for the localized nature of the response [<xref ref-type="bibr" rid="B33">33</xref>].</p><p>Surprisingly, a number of blood coagulation genes were highly expressed early during our <italic>in vitro </italic>infection (Fig. <xref ref-type="fig" rid="F2">2C</xref> and Table <xref ref-type="table" rid="T1">1</xref>), in particular TBXAS, which has been implicated in vasoconstriction, platelet aggregation, membrane lysis and increased permeability [<xref ref-type="bibr" rid="B34">34</xref>,<xref ref-type="bibr" rid="B35">35</xref>]; fibrin (FGB and FGG) and the coagulation pathway directly (SERPINs D1 and A3 together with Factors 10, 3 and 2). This gives a pro-coagulation profile, which mimics the clinical-pathological observations: at autopsy, many SARS patients have unusually disseminated small vessel thromboses in the lungs without evidence of disseminated intravascular coagulation [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B36">36</xref>]. Again, these expression profiles provide an experimental framework to explore an important aspect of SARS pathobiology and treatment.</p><p>It is interesting to note that the TLR9 was highly expressed in comparison to other TLR receptors, implying some degree of TLR specificity for the virus (Fig. <xref ref-type="fig" rid="F3">3A</xref>). TLR9 is known to respond to CpG signaling motifs (GTCGTT) [<xref ref-type="bibr" rid="B37">37</xref>-<xref ref-type="bibr" rid="B39">39</xref>] and one possibility is that the virus is activating directly through this mechanism. In support of this, we found that the SARS-CoV viral sequence contains the highest number (7 copies) of such specific signaling motifs compared to other coronaviruses and significantly more than several other viruses involved in respiratory diseases (Fig. <xref ref-type="fig" rid="F3">3B</xref>). It is conceivable that TLR9 may be aiding host recognition of the virus via the CpG groups and contributing to the initiation of the innate host inflammatory response. An alternative explanation is that TLR9 is being stimulated by mechanisms unrelated to CpG recognition.</p><p>The emerging picture from this study implicates a central role for the immune response in the pathobiology of a SARS infection. While detailed <italic>in vivo </italic>studies of the host response are now required, the <italic>in vitro </italic>model described here will allow responses to specific modulators (such as therapeutics) to be investigated. In future developments of the model, it will be interesting to compare the host response to different SARS-CoV isolates with inactivated preparations of the virus. In other diseases, <italic>in vitro </italic>models have revealed a number of key processes relevant to the clinical diseases [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>] and it is likely that the responses identified here will prove to be equally important. Although some clinical parameters have now been used as prognostic markers [<xref ref-type="bibr" rid="B40">40</xref>-<xref ref-type="bibr" rid="B42">42</xref>], further study of the regulatory mechanisms for chemokine-cytokine production will likely improve their accuracy and perhaps allow development of new treatment protocols.</p></sec></sec><sec><title>Competing interests</title><p>None declared.</p></sec><sec><title>Authors' contributions</title><p>LFPN, MLH, ETL and REC conceived the study, its design and coordination, results analysis and drafted the manuscript. EEO and KFT carried out the virus infections. SYN, KRKM, VNV and JMC were involved in the array and statistical analysis. JT carried out the real-time PCR assays.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2334/4/34/prepub"/></p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional File 1</title><p><bold>List of all immune related genes after SARS-CoV infection </bold>Comprehensive list of 1087 immune related genes that were altered in PBMCs in response to SARS-CoV infection at 4 hours, 8 hours, 12 hours, and 24 hours. Genes were grouped and ordered using the algorithm described in Methods. Rows represent individual genes, columns represent individual time points. Each cell in the matrix represents the mean expression level from 3 subjects for a gene feature at a particular time point (non-infected PBMCs responses have been subtracted from infected responses). The red and green color bars reflect high and low expression levels respectively, while black indicates equivalent expression level. The magnitude of the log-transformed ratio is reflected by the degree of color saturation. The line graph indicates the average expression ratios for each group. The area above the axis indicates upregulation, while the area under the axis means downregulation.</p></caption><media xlink:href="1471-2334-4-34-S1.pdf" mimetype="application" mime-subtype="pdf"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ack><sec><title>Acknowledgment</title><p>This study was supported by grants from the Agency for Science, Technology and Research (A*STAR), Singapore. Lisa F. P. Ng is also supported by a postdoctoral scholarship from the Singapore Millennium Foundation, Singapore Technologies. We thank Lora V. Agathe, Patricia Tay Pei-Wen, Khoo Chen-Ai and Li Pin (Genome Institute of Singapore); Renita Danabalan (National Environment Agency) for technical assistance and Dr Ling Ai-Ee (Department of Pathology, Singapore General Hospital) for the SARS-CoV isolate.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peiris</surname><given-names>JSM</given-names></name><name><surname>Lai</surname><given-names>ST</given-names></name><name><surname>Poon</surname><given-names>LLM</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Yam</surname><given-names>LY</given-names></name><name><surname>Lim</surname><given-names>W</given-names></name><name><surname>Nicholls</surname><given-names>J</given-names></name><name><surname>Yee</surname><given-names>WK</given-names></name><name><surname>Yan</surname><given-names>WW</given-names></name><name><surname>Cheung</surname><given-names>MT</given-names></name><name><surname>Cheng</surname><given-names>VC</given-names></name><name><surname>Chan</surname><given-names>KH</given-names></name><name><surname>Tsang</surname><given-names>DN</given-names></name><name><surname>Yung</surname><given-names>RW</given-names></name><name><surname>Ng</surname><given-names>TK</given-names></name><name><surname>Yeun</surname><given-names>KY</given-names></name><collab>SARS study group</collab></person-group><article-title>Coronavirus as a possible caused of severe acute respiratory syndrome</article-title><source>Lancet</source><year>2003</year><volume>361</volume><fpage>1319</fpage><lpage>1325</lpage><pub-id pub-id-type="pmid">12711465</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(03)13077-2</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ksiazek</surname><given-names>TG</given-names></name><name><surname>Erdman</surname><given-names>D</given-names></name><name><surname>Goldsmith</surname><given-names>CS</given-names></name><name><surname>Zaki</surname><given-names>SR</given-names></name><name><surname>Peret</surname><given-names>T</given-names></name><name><surname>Emery</surname><given-names>S</given-names></name><name><surname>Tong</surname><given-names>S</given-names></name><name><surname>Urbani</surname><given-names>C</given-names></name><name><surname>Comer</surname><given-names>JA</given-names></name><name><surname>Lim</surname><given-names>W</given-names></name><name><surname>Rollin</surname><given-names>PE</given-names></name><name><surname>Dowell</surname><given-names>SF</given-names></name><name><surname>Ling</surname><given-names>AE</given-names></name><name><surname>Humphrey</surname><given-names>CD</given-names></name><name><surname>Shieh</surname><given-names>WJ</given-names></name><name><surname>Guarner</surname><given-names>J</given-names></name><name><surname>Paddock</surname><given-names>CD</given-names></name><name><surname>Rota</surname><given-names>P</given-names></name><name><surname>Fields</surname><given-names>B</given-names></name><name><surname>DeRisi</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>JY</given-names></name><name><surname>Cox</surname><given-names>N</given-names></name><name><surname>Hughes</surname><given-names>JM</given-names></name><name><surname>LeDuc</surname><given-names>JW</given-names></name><name><surname>Bellini</surname><given-names>WJ</given-names></name><name><surname>Anderson</surname><given-names>LJ</given-names></name><collab>SARS Working Group</collab></person-group><article-title>A novel coronavirus associated with severe acute respiratory syndrome</article-title><source>N Engl J Med</source><year>2003</year><volume>348</volume><fpage>1953</fpage><lpage>1966</lpage><pub-id pub-id-type="pmid">12690092</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa030781</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Drosten</surname><given-names>C</given-names></name><name><surname>Gunther</surname><given-names>S</given-names></name><name><surname>Preiser</surname><given-names>W</given-names></name><name><surname>van der Werf</surname><given-names>S</given-names></name><name><surname>Brodt</surname><given-names>HR</given-names></name><name><surname>Becker</surname><given-names>S</given-names></name><name><surname>Rabenau</surname><given-names>H</given-names></name><name><surname>Panning</surname><given-names>M</given-names></name><name><surname>Kolesnikova</surname><given-names>L</given-names></name><name><surname>Fouchier</surname><given-names>RA</given-names></name><name><surname>Berger</surname><given-names>A</given-names></name><name><surname>Burguiere</surname><given-names>AM</given-names></name><name><surname>Cinatl</surname><given-names>J</given-names></name><name><surname>Eickmann</surname><given-names>M</given-names></name><name><surname>Escriou</surname><given-names>N</given-names></name><name><surname>Grywna</surname><given-names>K</given-names></name><name><surname>Kramme</surname><given-names>S</given-names></name><name><surname>Manuguerra</surname><given-names>JC</given-names></name><name><surname>Muller</surname><given-names>S</given-names></name><name><surname>Rickerts</surname><given-names>V</given-names></name><name><surname>Sturmer</surname><given-names>M</given-names></name><name><surname>Vieth</surname><given-names>S</given-names></name><name><surname>Klenk</surname><given-names>HD</given-names></name><name><surname>Osterhaus</surname><given-names>AD</given-names></name><name><surname>Schmitz</surname><given-names>H</given-names></name><name><surname>Doerr</surname><given-names>HW</given-names></name></person-group><article-title>Identification of a novel coronavirus in patients with severe acute respiratory syndrome</article-title><source>N Engl J Med</source><year>2003</year><volume>348</volume><fpage>1967</fpage><lpage>1976</lpage><pub-id pub-id-type="pmid">12690091</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa030747</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marra</surname><given-names>MA</given-names></name><name><surname>Jones</surname><given-names>SJM</given-names></name><name><surname>Astell</surname><given-names>CR</given-names></name><name><surname>Holt</surname><given-names>RA</given-names></name><name><surname>Brooks-Wilson</surname><given-names>A</given-names></name><name><surname>Butterfield</surname><given-names>YS</given-names></name><name><surname>Khattra</surname><given-names>J</given-names></name><name><surname>Asano</surname><given-names>JK</given-names></name><name><surname>Barber</surname><given-names>SA</given-names></name><name><surname>Chan</surname><given-names>SY</given-names></name><name><surname>Cloutier</surname><given-names>A</given-names></name><name><surname>Coughlin</surname><given-names>SM</given-names></name><name><surname>Freeman</surname><given-names>D</given-names></name><name><surname>Girn</surname><given-names>N</given-names></name><name><surname>Griffith</surname><given-names>OL</given-names></name><name><surname>Leach</surname><given-names>SR</given-names></name><name><surname>Mayo</surname><given-names>M</given-names></name><name><surname>McDonald</surname><given-names>H</given-names></name><name><surname>Montgomery</surname><given-names>SB</given-names></name><name><surname>Pandoh</surname><given-names>PK</given-names></name><name><surname>Petrescu</surname><given-names>AS</given-names></name><name><surname>Robertson</surname><given-names>AG</given-names></name><name><surname>Schein</surname><given-names>JE</given-names></name><name><surname>Siddiqui</surname><given-names>A</given-names></name><name><surname>Smailus</surname><given-names>DE</given-names></name><name><surname>Stott</surname><given-names>JM</given-names></name><name><surname>Yang</surname><given-names>GS</given-names></name><name><surname>Plummer</surname><given-names>F</given-names></name><name><surname>Andonov</surname><given-names>A</given-names></name><name><surname>Artsob</surname><given-names>H</given-names></name><name><surname>Bastien</surname><given-names>N</given-names></name><name><surname>Bernard</surname><given-names>K</given-names></name><name><surname>Booth</surname><given-names>TF</given-names></name><name><surname>Bowness</surname><given-names>D</given-names></name><name><surname>Czub</surname><given-names>M</given-names></name><name><surname>Drebot</surname><given-names>M</given-names></name><name><surname>Fernando</surname><given-names>L</given-names></name><name><surname>Flick</surname><given-names>R</given-names></name><name><surname>Garbutt</surname><given-names>M</given-names></name><name><surname>Gray</surname><given-names>M</given-names></name><name><surname>Grolla</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>Feldmann</surname><given-names>H</given-names></name><name><surname>Meyers</surname><given-names>A</given-names></name><name><surname>Kabani</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Normand</surname><given-names>S</given-names></name><name><surname>Stroher</surname><given-names>U</given-names></name><name><surname>Tipples</surname><given-names>GA</given-names></name><name><surname>Tyler</surname><given-names>S</given-names></name><name><surname>Vogrig</surname><given-names>R</given-names></name><name><surname>Ward</surname><given-names>D</given-names></name><name><surname>Watson</surname><given-names>B</given-names></name><name><surname>Brunham</surname><given-names>RC</given-names></name><name><surname>Krajden</surname><given-names>M</given-names></name><name><surname>Petric</surname><given-names>M</given-names></name><name><surname>Skowronski</surname><given-names>DM</given-names></name><name><surname>Upton</surname><given-names>C</given-names></name><name><surname>Roper</surname><given-names>RL</given-names></name></person-group><article-title>The genome sequence of the SARS-associated coronavirus</article-title><source>Science</source><year>2003</year><volume>300</volume><fpage>1399</fpage><lpage>1404</lpage><pub-id pub-id-type="pmid">12730501</pub-id><pub-id pub-id-type="doi">10.1126/science.1085953</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rota</surname><given-names>PA</given-names></name><name><surname>Oberste</surname><given-names>MS</given-names></name><name><surname>Monroe</surname><given-names>SS</given-names></name><name><surname>Nix</surname><given-names>WA</given-names></name><name><surname>Campagnoli</surname><given-names>R</given-names></name><name><surname>Icenogle</surname><given-names>JP</given-names></name><name><surname>Penaranda</surname><given-names>S</given-names></name><name><surname>Bankamp</surname><given-names>B</given-names></name><name><surname>Maher</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>MH</given-names></name><name><surname>Tong</surname><given-names>S</given-names></name><name><surname>Tamin</surname><given-names>A</given-names></name><name><surname>Lowe</surname><given-names>L</given-names></name><name><surname>Frace</surname><given-names>M</given-names></name><name><surname>DeRisi</surname><given-names>JL</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Erdmann</surname><given-names>DD</given-names></name><name><surname>Peret</surname><given-names>TC</given-names></name><name><surname>Burns</surname><given-names>C</given-names></name><name><surname>Ksiazek</surname><given-names>TG</given-names></name><name><surname>Rollin</surname><given-names>PE</given-names></name><name><surname>Sanchez</surname><given-names>A</given-names></name><name><surname>Liffick</surname><given-names>S</given-names></name><name><surname>Holloway</surname><given-names>B</given-names></name><name><surname>Limor</surname><given-names>J</given-names></name><name><surname>McCaustland</surname><given-names>K</given-names></name><name><surname>Olsen-Rasmussen</surname><given-names>M</given-names></name><name><surname>Fouchier</surname><given-names>R</given-names></name><name><surname>Gunther</surname><given-names>S</given-names></name><name><surname>Osterhaus</surname><given-names>AD</given-names></name><name><surname>Drosten</surname><given-names>C</given-names></name><name><surname>Pallansch</surname><given-names>MA</given-names></name><name><surname>Anderson</surname><given-names>LJ</given-names></name><name><surname>Bellini</surname><given-names>WJ</given-names></name></person-group><article-title>Characterization of a novel coronavirus associated with severe acute respiratory syndrome</article-title><source>Science</source><year>2003</year><volume>300</volume><fpage>1394</fpage><lpage>1399</lpage><pub-id pub-id-type="pmid">12730500</pub-id><pub-id pub-id-type="doi">10.1126/science.1085952</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ruan</surname><given-names>YJ</given-names></name><name><surname>Wei</surname><given-names>CL</given-names></name><name><surname>Ling</surname><given-names>AE</given-names></name><name><surname>Vinsensius</surname><given-names>V</given-names></name><name><surname>Thoreau</surname><given-names/></name><name><surname>Se-Thoe</surname><given-names>SY</given-names></name><name><surname>Chia</surname><given-names>JM</given-names></name><name><surname>Ng</surname><given-names>WP</given-names></name><name><surname>Chiu</surname><given-names>KP</given-names></name><name><surname>Lim</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Chan</surname><given-names>KP</given-names></name><name><surname>Oon</surname><given-names>LE</given-names></name><name><surname>Ng</surname><given-names>ML</given-names></name><name><surname>Leo</surname><given-names>YS</given-names></name><name><surname>Ng</surname><given-names>LFP</given-names></name><name><surname>Ren</surname><given-names>EC</given-names></name><name><surname>Stanton</surname><given-names>LW</given-names></name><name><surname>Long</surname><given-names>PM</given-names></name><name><surname>Liu</surname><given-names>ET</given-names></name></person-group><article-title>Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection</article-title><source>Lancet</source><year>2003</year><volume>361</volume><fpage>1779</fpage><lpage>1785</lpage><pub-id pub-id-type="pmid">12781537</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(03)13414-9</pub-id></citation></ref><ref id="B7"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Holmes</surname><given-names>KV</given-names></name></person-group><person-group person-group-type="editor"><name><surname>BN Fields, DM Knipe</surname></name></person-group><article-title>Coronaviridae and their replication</article-title><source>In &#x000ab;Fields Virology&#x000bb;</source><year>1990</year><publisher-name>Raven Press, New York</publisher-name><fpage>841</fpage><lpage>856</lpage></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>GF</given-names></name><name><surname>Perlman</surname><given-names>S</given-names></name></person-group><article-title>Macrophage infiltration, but not apoptosis, is correlated with immune-mediated demyelination following murine infection with a neutropic coronavirus</article-title><source>J Virol</source><year>1999</year><volume>73</volume><fpage>8771</fpage><lpage>8780</lpage><pub-id pub-id-type="pmid">10482631</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>CY</given-names></name><name><surname>Poon</surname><given-names>LL</given-names></name><name><surname>Lau</surname><given-names>AS</given-names></name><name><surname>Luk</surname><given-names>W</given-names></name><name><surname>Lau</surname><given-names>YL</given-names></name><name><surname>Shortridge</surname><given-names>KF</given-names></name><name><surname>Gordon</surname><given-names>S</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Peiris</surname><given-names>JSM</given-names></name></person-group><article-title>Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human diseases?</article-title><source>Lancet</source><year>2002</year><volume>360</volume><fpage>1831</fpage><lpage>1837</lpage><pub-id pub-id-type="pmid">12480361</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(02)11772-7</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Julkunen</surname><given-names>I</given-names></name><name><surname>Melen</surname><given-names>K</given-names></name><name><surname>Nyqvist</surname><given-names>M</given-names></name><name><surname>Pirhonen</surname><given-names>J</given-names></name><name><surname>Sareneva</surname><given-names>T</given-names></name><name><surname>Matikainen</surname><given-names>S</given-names></name></person-group><article-title>Inflammatory responses in influenza A virus infection</article-title><source>Vaccine</source><year>2000</year><volume>19</volume><fpage>S32</fpage><lpage>S37</lpage><pub-id pub-id-type="pmid">11163460</pub-id><pub-id pub-id-type="doi">10.1016/S0264-410X(00)00275-9</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arndt</surname><given-names>U</given-names></name><name><surname>Wennemuth</surname><given-names>G</given-names></name><name><surname>Barth</surname><given-names>P</given-names></name><name><surname>Nain</surname><given-names>M</given-names></name><name><surname>Al-Abed</surname><given-names>Y</given-names></name><name><surname>Meinhardt</surname><given-names>A</given-names></name><name><surname>Gemsa</surname><given-names>D</given-names></name><name><surname>Bacher</surname><given-names>M</given-names></name></person-group><article-title>Release of macrophage migration inhibitory factor and CXCL8/interleukin-8 from lung epithelial cells rendered necrotic by influenza A virus infection</article-title><source>J Virol</source><year>2002</year><volume>76</volume><fpage>9298</fpage><lpage>9306</lpage><pub-id pub-id-type="pmid">12186913</pub-id><pub-id pub-id-type="doi">10.1128/JVI.76.18.9298-9306.2002</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nau</surname><given-names>GJ</given-names></name><name><surname>Richmond</surname><given-names>JFL</given-names></name><name><surname>Schlesinger</surname><given-names>A</given-names></name><name><surname>Jennings</surname><given-names>E.</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Young</surname><given-names>R</given-names></name></person-group><article-title>Human macrophage activation programs induced by bacterial pathogens</article-title><source>Proc Natl Acad Sci USA</source><year>2002</year><volume>99</volume><fpage>1503</fpage><lpage>1508</lpage><pub-id pub-id-type="pmid">11805289</pub-id><pub-id pub-id-type="doi">10.1073/pnas.022649799</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>DY</given-names></name><name><surname>Majewski</surname><given-names>P</given-names></name><name><surname>Schulte</surname><given-names>LC</given-names></name><name><surname>Korn</surname><given-names>JM</given-names></name><name><surname>Young</surname><given-names>RA</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Hacohen</surname><given-names>N</given-names></name></person-group><article-title>The plasticity of dendritic cell responses to pathogens and their components</article-title><source>Science</source><year>2001</year><volume>294</volume><fpage>870</fpage><lpage>875</lpage><pub-id pub-id-type="pmid">11679675</pub-id><pub-id pub-id-type="doi">10.1126/science.294.5543.870</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nicholls</surname><given-names>JM</given-names></name><name><surname>Poon</surname><given-names>LL</given-names></name><name><surname>Lee</surname><given-names>KC</given-names></name><name><surname>Ng</surname><given-names>WF</given-names></name><name><surname>Lai</surname><given-names>ST</given-names></name><name><surname>Leung</surname><given-names>CY</given-names></name><name><surname>Chu</surname><given-names>CM</given-names></name><name><surname>Hui</surname><given-names>PK</given-names></name><name><surname>Mak</surname><given-names>KL</given-names></name><name><surname>Lim</surname><given-names>W</given-names></name><name><surname>Yan</surname><given-names>KW</given-names></name><name><surname>Chan</surname><given-names>KH</given-names></name><name><surname>Tsang</surname><given-names>NC</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Yue</surname><given-names>KY</given-names></name><name><surname>Peiris</surname><given-names>JS</given-names></name></person-group><article-title>Lung pathogen of fatal severe acute respiratory syndrom</article-title><source>Lancet</source><year>2003</year><volume>361</volume><fpage>1773</fpage><lpage>1778</lpage><pub-id pub-id-type="pmid">12781536</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(03)13413-7</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Wo</surname><given-names>J</given-names></name><name><surname>Shao</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Yao</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>M</given-names></name><name><surname>Dennin</surname><given-names>R</given-names></name></person-group><article-title>SARS-coronavirus replicates in mononuclear cells of peripheral blood (PBMCs) from SARS patients</article-title><source>J Clin Virol</source><year>2003</year><volume>28</volume><fpage>239</fpage><lpage>244</lpage><pub-id pub-id-type="pmid">14522061</pub-id><pub-id pub-id-type="doi">10.1016/S1386-6532(03)00195-1</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gillim-Ross</surname><given-names>L</given-names></name><name><surname>Taylor</surname><given-names>J</given-names></name><name><surname>Scholl</surname><given-names>DR</given-names></name><name><surname>Ridenour</surname><given-names>J</given-names></name><name><surname>Masters</surname><given-names>PS</given-names></name><name><surname>Wenworth</surname><given-names>DE</given-names></name></person-group><article-title>Discovery of novel human and animal cells infected by the severe acute respiratory syndrome coronavirus by replication-specific multiplex reverse transcription-PCR</article-title><source>J Clin Microbiol</source><year>2004</year><volume>42</volume><fpage>3196</fpage><lpage>3206</lpage><pub-id pub-id-type="pmid">15243082</pub-id><pub-id pub-id-type="doi">10.1128/JCM.42.7.3196-3206.2004</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Raza</surname><given-names>MW</given-names></name><name><surname>Blackwell</surname><given-names>CC</given-names></name><name><surname>Elton</surname><given-names>RA</given-names></name><name><surname>Weir</surname><given-names>DM</given-names></name></person-group><article-title>Bacterial activity of a monocytic cell line (THP-1) against common respiratory tract bacterial pathogens is depressed after infection with respiratory syncytial virus</article-title><source>J Med Microbiol</source><year>2000</year><volume>49</volume><fpage>227</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">10707942</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>K</given-names></name><name><surname>Ooi</surname><given-names>EE</given-names></name><name><surname>Kumarsil</surname><given-names>B</given-names></name><name><surname>Saw</surname><given-names>S</given-names></name><name><surname>Sethi</surname><given-names>S</given-names></name></person-group><article-title>Severe acute respiratory syndrome without respiratory symptoms or abnormal chest radiograph findings</article-title><source>Clin Infect Dis</source><year>2004</year><volume>38</volume><fpage>585</fpage><lpage>586</lpage><pub-id pub-id-type="pmid">14765354</pub-id><pub-id pub-id-type="doi">10.1086/381437</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Traggiai</surname><given-names>E</given-names></name><name><surname>Becker</surname><given-names>S</given-names></name><name><surname>Sbbarao</surname><given-names>K</given-names></name><name><surname>Kolesnikova</surname><given-names>L</given-names></name><name><surname>Uematsu</surname><given-names>Y</given-names></name><name><surname>Gismondo</surname><given-names>MR</given-names></name><name><surname>Murphy</surname><given-names>BR</given-names></name><name><surname>Rappuoli</surname><given-names>R</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name></person-group><article-title>An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus</article-title><source>Nat Med</source><year>2004</year><volume>10</volume><fpage>871</fpage><lpage>875</lpage><pub-id pub-id-type="pmid">15247913</pub-id><pub-id pub-id-type="doi">10.1038/nm1080</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Wan</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Cao</surname><given-names>C</given-names></name></person-group><article-title>Antibody responses against SARS-coronavirus and its nucleocapsid in SARS patients</article-title><source>J Clin Virol</source><year>2004</year><volume>31</volume><fpage>66</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">15288616</pub-id><pub-id pub-id-type="doi">10.1016/j.jcv.2004.05.006</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>S</given-names></name></person-group><article-title>Alternative activation of macrophages</article-title><source>Nat Rev Immunol</source><year>2003</year><volume>3</volume><fpage>23</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">12511873</pub-id><pub-id pub-id-type="doi">10.1038/nri978</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>YC</given-names></name><name><surname>Liang</surname><given-names>WG</given-names></name><name><surname>Chen</surname><given-names>FW</given-names></name><name><surname>Hsu</surname><given-names>JH</given-names></name><name><surname>Yang</surname><given-names>JJ</given-names></name><name><surname>Chang</surname><given-names>MS</given-names></name></person-group><article-title>IL-19 induces production of IL-6 and TNF-alpha and results in cell apoptosis through TNF-alpha</article-title><source>J Immunol</source><year>2002</year><volume>169</volume><fpage>4288</fpage><lpage>4297</lpage><pub-id pub-id-type="pmid">12370360</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><collab>Beijing Group of National Research projects for SARS</collab></person-group><article-title>Dynamic changes in blood cytokine levels as clinical indicators in severe acute respiratory syndrome</article-title><source>Chin Med J</source><year>2003</year><volume>116</volume><fpage>1283</fpage><lpage>1287</lpage><pub-id pub-id-type="pmid">14527349</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>To</surname><given-names>K</given-names></name><name><surname>Tong</surname><given-names>JH</given-names></name><name><surname>Chan</surname><given-names>PK</given-names></name><name><surname>Au</surname><given-names>FW</given-names></name><name><surname>Chim</surname><given-names>SS</given-names></name><name><surname>Chan</surname><given-names>AK</given-names></name><name><surname>Cheung</surname><given-names>JL</given-names></name><name><surname>Liu</surname><given-names>EY</given-names></name><name><surname>Tse</surname><given-names>V</given-names></name><name><surname>Lo</surname><given-names>AW</given-names></name><name><surname>Lo</surname><given-names>D</given-names></name><name><surname>Ng</surname><given-names>H</given-names></name></person-group><article-title>Tissue and cellular tropism of the coronavirus associated with severe acute respiratory syndrome: an in-situ hybridization study of fatal cases</article-title><source>J Pathol</source><year>2004</year><volume>202</volume><fpage>157</fpage><lpage>163</lpage><pub-id pub-id-type="pmid">14743497</pub-id><pub-id pub-id-type="doi">10.1002/path.1510</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cinatl</surname><given-names>J</given-names></name><name><surname>Morgenstern</surname><given-names>B</given-names></name><name><surname>Bauer</surname><given-names>G</given-names></name><name><surname>Chandra</surname><given-names>P</given-names></name><name><surname>Rabenau</surname><given-names>H</given-names></name><name><surname>Doerr</surname><given-names>HW</given-names></name></person-group><article-title>Treatment of SARS with human interferons</article-title><source>Lancet</source><year>2003</year><volume>362</volume><fpage>293</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">12892961</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(03)13973-6</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>MJ</given-names></name></person-group><article-title>Role of chemokines in the biology of natural killer cells</article-title><source>J Leukoc Biol</source><year>2002</year><volume>71</volume><fpage>173</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">11818437</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miyamoto</surname><given-names>M</given-names></name><name><surname>Prause</surname><given-names>O</given-names></name><name><surname>Sjostrand</surname><given-names>M</given-names></name><name><surname>Laan</surname><given-names>M</given-names></name><name><surname>Lotvall</surname><given-names>J</given-names></name><name><surname>Linden</surname><given-names>A</given-names></name></person-group><article-title>Endogenous IL-17 as a mediator of neutrophil recruitment caused by endotoxin exposure in mouse airways</article-title><source>J Immunol</source><year>2003</year><volume>170</volume><fpage>4665</fpage><lpage>4672</lpage><pub-id pub-id-type="pmid">12707345</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Drost</surname><given-names>EW</given-names></name><name><surname>MacNee</surname><given-names>W</given-names></name></person-group><article-title>Potential role of IL-8, platelet-activating factor and TNF-alpha in the sequestration of neutrophils in the lung: effects on neutrophil deformability, adhesion receptor expression, and chemotaxis</article-title><source>Eur J Immunol</source><year>2002</year><volume>32</volume><fpage>393</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">11813158</pub-id><pub-id pub-id-type="doi">10.1002/1521-4141(200202)32:2&#x0003c;393::AID-IMMU393&#x0003e;3.0.CO;2-5</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aggarwal</surname><given-names>A</given-names></name><name><surname>Baker</surname><given-names>CS</given-names></name><name><surname>Evans</surname><given-names>TW</given-names></name><name><surname>Haslam</surname><given-names>PL</given-names></name></person-group><article-title>G-CSF and IL-8 but not GM-CSF correlate with severity of pulmonary neutrophilia in acute respiratory distress syndrome</article-title><source>Eur Respir J</source><year>2000</year><volume>15</volume><fpage>895</fpage><lpage>901</lpage><pub-id pub-id-type="pmid">10853855</pub-id><pub-id pub-id-type="doi">10.1034/j.1399-3003.2000.15e14.x</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buhling</surname><given-names>F</given-names></name><name><surname>Ittenson</surname><given-names>A</given-names></name><name><surname>Kaiser</surname><given-names>D</given-names></name><name><surname>Tholert</surname><given-names>G</given-names></name><name><surname>Hoffmann</surname><given-names>B</given-names></name><name><surname>Reinhold</surname><given-names>D</given-names></name><name><surname>Ansorge</surname><given-names>S</given-names></name><name><surname>Welte</surname><given-names>T</given-names></name></person-group><article-title>MRP8/MRO14, CD11b and HLA-DR expression of alveolar macrophages in pneumonia</article-title><source>Immunol Lett</source><year>2000</year><volume>71</volume><fpage>185</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">10722871</pub-id><pub-id pub-id-type="doi">10.1016/S0165-2478(00)00164-4</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sar</surname><given-names>B</given-names></name><name><surname>Oishi</surname><given-names>K</given-names></name><name><surname>Matsushima</surname><given-names>K</given-names></name><name><surname>Nagatake</surname><given-names>T</given-names></name></person-group><article-title>Induction of interleukin 8 (IL-8) production by pseudomonas nitrite reductase in human alveolar macrophages and epithelial cells</article-title><source>Microbiol Immunol</source><year>1999</year><volume>43</volume><fpage>409</fpage><lpage>417</lpage><pub-id pub-id-type="pmid">10449247</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pace</surname><given-names>E</given-names></name><name><surname>Gjomarkaj</surname><given-names>M</given-names></name><name><surname>Melis</surname><given-names>M</given-names></name><name><surname>Profita</surname><given-names>M</given-names></name><name><surname>Spatafora</surname><given-names>M</given-names></name><name><surname>Vignola</surname><given-names>AM</given-names></name><name><surname>Bonsignore</surname><given-names>G</given-names></name><name><surname>Mody</surname><given-names>CH</given-names></name></person-group><article-title>Interleukin-8 induces lymphocyte chemotaxis into the pleural space. Role of pleural macrophages</article-title><source>Am J Respir Crit Care Med</source><year>1999</year><volume>159</volume><fpage>1592</fpage><lpage>1599</lpage><pub-id pub-id-type="pmid">10228132</pub-id></citation></ref><ref id="B33"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>PC</given-names></name><name><surname>Lam</surname><given-names>CW</given-names></name><name><surname>Li</surname><given-names>AM</given-names></name><name><surname>Wong</surname><given-names>CK</given-names></name><name><surname>Cheng</surname><given-names>FW</given-names></name><name><surname>Leung</surname><given-names>TF</given-names></name><name><surname>Hon</surname><given-names>EK</given-names></name><name><surname>Chan</surname><given-names>IH</given-names></name><name><surname>Li</surname><given-names>CK</given-names></name><name><surname>Fung</surname><given-names>KS</given-names></name><name><surname>Fok</surname><given-names>TS</given-names></name></person-group><article-title>Inflammatory cytokine profile in children with severe</article-title></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ball</surname><given-names>HA</given-names></name><name><surname>Cook</surname><given-names>JA</given-names></name><name><surname>Wise</surname><given-names>WC</given-names></name><name><surname>Halushka</surname><given-names>PV</given-names></name></person-group><article-title>Role of thromboxane, prostaglandins and leukotrienes in endotoxic and septic shock</article-title><source>Intensive Care Med</source><year>1986</year><volume>12</volume><fpage>116</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">3016060</pub-id><pub-id pub-id-type="doi">10.1007/BF00254925</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zaitsu</surname><given-names>M</given-names></name><name><surname>Hamasaki</surname><given-names>Y</given-names></name><name><surname>Nishimura</surname><given-names>S</given-names></name><name><surname>Matsuo</surname><given-names>M</given-names></name><name><surname>Fujita</surname><given-names>I</given-names></name><name><surname>Thromboxane</surname><given-names>IE</given-names></name></person-group><article-title>Thromoxane synthesis is increased by upregulation of cytosolic phospholipase A2 and cyclooxygenase-2 in peripheral polymorphonuclear leukocytes during bacterial infection in childhood</article-title><source>Am J Hematol</source><year>2003</year><volume>72</volume><fpage>115</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">12555215</pub-id><pub-id pub-id-type="doi">10.1002/ajh.10280</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Franks</surname><given-names>TJ</given-names></name><name><surname>Chong</surname><given-names>PY</given-names></name><name><surname>Chui</surname><given-names>P</given-names></name><name><surname>Galvin</surname><given-names>JR</given-names></name><name><surname>Lourens</surname><given-names>RM</given-names></name><name><surname>Reid</surname><given-names>AH</given-names></name><name><surname>Selbs</surname><given-names>E</given-names></name><name><surname>McEvoy</surname><given-names>CP</given-names></name><name><surname>Hayden</surname><given-names>CDL</given-names></name><name><surname>Fukuoka</surname><given-names>J</given-names></name><name><surname>Taubenberger</surname><given-names>JK</given-names></name><name><surname>Travis</surname><given-names>W</given-names></name></person-group><article-title>Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore</article-title><source>Hum Pathol</source><year>2003</year><volume>34</volume><fpage>729</fpage><pub-id pub-id-type="pmid">12874774</pub-id><pub-id pub-id-type="doi">10.1016/S0046-8177(03)00365-4</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akira</surname><given-names>S</given-names></name><name><surname>Hemmi</surname><given-names>H</given-names></name></person-group><article-title>Recognition of pathogen-associated molecular patterns by TLR family</article-title><source>Immunol Lett</source><year>2003</year><volume>85</volume><fpage>85</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">12527213</pub-id><pub-id pub-id-type="doi">10.1016/S0165-2478(02)00228-6</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hornung</surname><given-names>V</given-names></name><name><surname>Rothenfusser</surname><given-names>S</given-names></name><name><surname>Britsch</surname><given-names>S</given-names></name><name><surname>Krug</surname><given-names>A</given-names></name><name><surname>Jahrsdorfer</surname><given-names>B</given-names></name><name><surname>Giese</surname><given-names>T</given-names></name><name><surname>Endres</surname><given-names>S</given-names></name><name><surname>Hartmann</surname><given-names>G</given-names></name></person-group><article-title>Quantitative expression of toll-like receptor 1&#x02013;10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides</article-title><source>J Immunol</source><year>2002</year><volume>168</volume><fpage>4531</fpage><lpage>4537</lpage><pub-id pub-id-type="pmid">11970999</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hemmi</surname><given-names>H</given-names></name><name><surname>Takeuchi</surname><given-names>O</given-names></name><name><surname>Kawai</surname><given-names>T</given-names></name><name><surname>Kaisho</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Sanjo</surname><given-names>H</given-names></name><name><surname>Matsumoto</surname><given-names>M</given-names></name><name><surname>Hoshino</surname><given-names>K</given-names></name><name><surname>Wagner</surname><given-names>H</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name></person-group><article-title>A Toll-like receptor recognizes bacterial DNA</article-title><source>Nature</source><year>2000</year><volume>408</volume><fpage>740</fpage><lpage>745</lpage><pub-id pub-id-type="pmid">11130078</pub-id><pub-id pub-id-type="doi">10.1038/35047123</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Xin</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Mao</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Chang</surname><given-names>B</given-names></name><name><surname>Chang</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name></person-group><article-title>Prognostic factors for severe acute respiratory syndrome: a clinical analysis of 165 cases</article-title><source>Clin Infect Dis</source><year>2004</year><volume>38</volume><fpage>483</fpage><lpage>489</lpage><pub-id pub-id-type="pmid">14765339</pub-id><pub-id pub-id-type="doi">10.1086/380973</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>NS</given-names></name><name><surname>Chung</surname><given-names>T</given-names></name><name><surname>Konen</surname><given-names>E</given-names></name><name><surname>Roberts</surname><given-names>HC</given-names></name><name><surname>Rao</surname><given-names>TN</given-names></name><name><surname>Gold</surname><given-names>WL</given-names></name><name><surname>Mehta</surname><given-names>S</given-names></name><name><surname>Tomlinson</surname><given-names>GA</given-names></name><name><surname>Boylan</surname><given-names>CE</given-names></name><name><surname>Grossman</surname><given-names>H</given-names></name><name><surname>Hong</surname><given-names>HH</given-names></name><name><surname>Weisbrod</surname><given-names>GL</given-names></name></person-group><article-title>Pattern of disease in patients with severe acute respiratory syndrome</article-title><source>AJR Am J Roentgenol</source><year>2004</year><volume>182</volume><fpage>493</fpage><lpage>498</lpage><pub-id pub-id-type="pmid">14736688</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>CP</given-names></name><name><surname>Chiang</surname><given-names>WC</given-names></name><name><surname>Ma</surname><given-names>MH</given-names></name><name><surname>Chen</surname><given-names>SY</given-names></name><name><surname>Hsu</surname><given-names>CY</given-names></name><name><surname>Ko</surname><given-names>PC</given-names></name><name><surname>Tsai</surname><given-names>KC</given-names></name><name><surname>Fan</surname><given-names>CM</given-names></name><name><surname>Shih</surname><given-names>FY</given-names></name><name><surname>Chen</surname><given-names>SC</given-names></name><name><surname>Chen</surname><given-names>YC</given-names></name><name><surname>Chang</surname><given-names>SC</given-names></name><name><surname>Chen</surname><given-names>WJ</given-names></name></person-group><article-title>Validation of a novel severe acute respiratory syndrome scoring system</article-title><source>Ann Emerg Med</source><year>2004</year><volume>43</volume><fpage>34</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">14707938</pub-id><pub-id pub-id-type="doi">10.1016/j.annemergmed.2003.10.042</pub-id></citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Tables</title><fig position="float" id="F1"><label>Figure 1</label><caption><p>Kinetics of SARS-CoV replication. A. Viral copy number per well during culture. Two MOI infecting doses were used, 0.1 (&#x025b2;,&#x025a0;) and 0.01 (&#x025a1;,&#x025b3;) with 2 &#x000d7; 10<sup>5 </sup>PBMCs/well. Harvested PBMCs were separated into two fractions, adherent cells (mostly macrophages), (&#x025a0;,&#x025b3;) and suspended cells (mostly lymphocytes), (&#x025b2;,&#x025a1;). Points represent the mean of six subjects, each done in duplicate. Increasing viral copy number is clearly seen in adherent cells using an MOI of 0.1. There was little increase in viral load in non-adherent cells infected with SARS- CoV. B. Replication of SARS-CoV in the THP-1 cell line. Using an MOI of 0.1, fold increase from day 0 in SARS-CoV infected THP-1 cells (&#x025c6;) was similar to the PBMCs adherent fraction (&#x025b2;). Infections were done in duplicate and assayed in duplicate. Error bars represent SEM. C. Variation in the PBMC response to SARS-CoV infection. Using an MOI of 0.1 adherent cells (&#x025a0;) but not suspended cells (&#x025b2;) showed differing lag phase length and viral replication in 6 subjects (a to f). Points show means of two replicates.</p></caption><graphic xlink:href="1471-2334-4-34-1"/></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p>SARS specific gene expression changes. A. Plot showing the variance of expression ratio for each of the gene features across all the time points. Dotted line indicates the ~1200 most variable gene features. B. Expression ratios of ~1200 gene features as grouped by the algorithm as discussed in Methods. Rows represent individual genes, columns represent individual time points. Each cell in the matrix represents the mean expression level from 3 subjects for a gene feature at a particular time point (non-infected PBMCs responses have been subtracted from infected responses). The red and green color bars reflect high and low expression levels respectively, while black indicates equivalent expression level. The magnitude of the log-transformed ratio is reflected by the degree of color saturation. C. Levels of PBMCs mRNA expression of 1087 immune-related genes at 4 hours, 8 hours, 12 hours, and 24 hours in response to SARS-CoV infection were grouped and ordered using the algorithm described in Methods. Rows represent individual genes, columns represent individual time points. Each cell in the matrix represents the mean expression level from 3 subjects for a gene feature at a particular time point (non-infected PBMCs responses have been subtracted from infected responses). The red and green color bars reflect high and low expression levels respectively, while black indicates equivalent expression level. The magnitude of the log-transformed ratio is reflected by the degree of color saturation. The line graph indicates the average expression ratios for each group. The area above the axis indicates upregulation, while the area under the axis means downregulation.</p></caption><graphic xlink:href="1471-2334-4-34-2"/></fig><fig position="float" id="F3"><label>Figure 3</label><caption><p>Expression of TLR9 in response to SARS-CoV infection. A. Expression range (log<sub>2</sub>) for TLR9, TLR2 and TLR4. The expression range for TLR9 was greater than expected (* represents a <italic>P</italic>-value for TLR9 of 0.016). B. Comparison of the CpG motif (GTCGTT) copy number in coronaviruses and other viruses linked to respiratory diseases. Accession numbers are as follows: SARS coronavirus SIN2500 &#x02013; AY283794, Human coronavirus 229E &#x02013; NC_002645, Murine hepatitis virus &#x02013; NC_001846, Avian infectious bronchitis virus &#x02013; NC_001451, Bovine coronavirus &#x02013; NC_003045, Human rhinovirus B &#x02013; NC_001490, Human parainfluenza virus 1 &#x02013; NC_003461, Human respiratory syncytial virus &#x02013; NC_001781, Human metapneumovirus &#x02013; NC_004148.</p></caption><graphic xlink:href="1471-2334-4-34-3"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Representation of selected immune-related genes upregulated during the first 12 hours post-infection.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Gene</bold></td><td align="left"><bold>Unique Gene ID.</bold></td><td align="left"><bold>Function</bold></td><td align="left"><bold>Expression range (log<sub>2</sub>)</bold></td><td align="left"><bold>Cluster no.</bold></td></tr></thead><tbody><tr><td align="left" colspan="5"><bold>
                              <italic>Immune Response Genes:</italic>
                           </bold></td></tr><tr><td align="left">TGFBR1</td><td align="left">Hs.220</td><td align="left">Cytokine proinflammatory</td><td align="left">10.66</td><td align="left">4</td></tr><tr><td align="left">CD36</td><td align="left">Hs.75613</td><td align="left">Macrophage receptor</td><td align="left">8.61</td><td align="left">3</td></tr><tr><td align="left">TLR 9</td><td align="left">Hs.87968</td><td align="left">Macrophage activation</td><td align="left">7.11</td><td align="left">7</td></tr><tr><td align="left">MST</td><td align="left">Hs.349110</td><td align="left">Macrophage activation</td><td align="left">7.07</td><td align="left">6</td></tr><tr><td align="left">IL 19</td><td align="left">Hs.71979</td><td align="left">Cytokine, proinflammatory</td><td align="left">6.86</td><td align="left">9</td></tr><tr><td align="left">C1QR</td><td align="left">Hs.97199</td><td align="left">Innate response</td><td align="left">6.31</td><td align="left">7</td></tr><tr><td align="left">C6</td><td align="left">Hs.1282</td><td align="left">Innate response</td><td align="left">6.22</td><td align="left">6</td></tr><tr><td align="left">GATA3</td><td align="left">Hs.169946</td><td align="left">Inflamation signaling</td><td align="left">6.14</td><td align="left">9</td></tr><tr><td align="left">MMD</td><td align="left">Hs.79889</td><td align="left">Monocyte to macrophage</td><td align="left">6.13</td><td align="left">7</td></tr><tr><td align="left">CCL 25</td><td align="left">Hs.50404</td><td align="left">Chemokine, trafficking</td><td align="left">6.10</td><td align="left">6</td></tr><tr><td align="left">CXCL 12</td><td align="left">Hs.237356</td><td align="left">Chemokine, trafficking</td><td align="left">5.86</td><td align="left">6</td></tr><tr><td align="left">CCL 27</td><td align="left">Hs.225948</td><td align="left">Chemokine, trafficking</td><td align="left">5.34</td><td align="left">6</td></tr><tr><td align="left">C4BPB</td><td align="left">Hs.99886</td><td align="left">Innate response</td><td align="left">5.12</td><td align="left">6</td></tr><tr><td align="left">CCR 4</td><td align="left">Hs.184926</td><td align="left">Chemokine, trafficking</td><td align="left">5.11</td><td align="left">3</td></tr><tr><td align="left">CCL 4</td><td align="left">Hs.75703</td><td align="left">Chemokine, trafficking</td><td align="left">4.62</td><td align="left">3</td></tr><tr><td align="left">IL 17C</td><td align="left">Hs.110040</td><td align="left">Chemokine, trafficking</td><td align="left">4.25</td><td align="left">14</td></tr><tr><td align="left">IL 1&#x003b2;</td><td align="left">Hs.126256</td><td align="left">Cytokine, proinflammatory</td><td align="left">4.20</td><td align="left">3</td></tr><tr><td align="left">MRC 2</td><td align="left">Hs.7835</td><td align="left">Macrophage activation</td><td align="left">3.20</td><td align="left">7</td></tr><tr><td align="left">CXCL 9</td><td align="left">Hs.77367</td><td align="left">Chemokine, trafficking</td><td align="left">3.00</td><td align="left">2</td></tr><tr><td align="left">CCL 20</td><td align="left">Hs.75498</td><td align="left">Chemokine, trafficking</td><td align="left">2.88</td><td align="left">3</td></tr><tr><td align="left">CXCL 3</td><td align="left">Hs.89690</td><td align="left">Chemokine, trafficking</td><td align="left">2.79</td><td align="left">13</td></tr><tr><td align="left">CXCL 2</td><td align="left">Hs.75765</td><td align="left">Chemokine, trafficking</td><td align="left">2.78</td><td align="left">3</td></tr><tr><td align="left">CD 14</td><td align="left">Hs.75627</td><td align="left">Macrophage activation</td><td align="left">2.73</td><td align="left">3</td></tr><tr><td align="left">IL 8</td><td align="left">Hs.624</td><td align="left">Chemokine, trafficking</td><td align="left">2.70</td><td align="left">3</td></tr><tr><td align="left">NF&#x003ba;&#x003b2;1</td><td align="left">Hs.83428</td><td align="left">Macrophage activation</td><td align="left">2.61</td><td align="left">13</td></tr><tr><td align="left">CCL 22</td><td align="left">Hs.97203</td><td align="left">Chemokine, trafficking</td><td align="left">2.60</td><td align="left">3</td></tr><tr><td align="left">CCR 7</td><td align="left">Hs.1652</td><td align="left">Chemokine, trafficking</td><td align="left">2.55</td><td align="left">9</td></tr><tr><td align="left" colspan="5"><bold>
                              <italic>Blood Coagulation Genes:</italic>
                           </bold></td></tr><tr><td align="left">SERPINA3</td><td align="left">Hs.234726</td><td align="left">Inflammation activation</td><td align="left">9.39</td><td align="left">3</td></tr><tr><td align="left">SERPINI2</td><td align="left">Hs.158308</td><td align="left">Proteinase inhibitor</td><td align="left">8.82</td><td align="left">11</td></tr><tr><td align="left">TBXAS 1</td><td align="left">Hs.2001</td><td align="left">Blood coagulation</td><td align="left">7.70</td><td align="left">8</td></tr><tr><td align="left">FGB</td><td align="left">Hs.7645</td><td align="left">Fibrin</td><td align="left">6.75</td><td align="left">4</td></tr><tr><td align="left">SERPIND1</td><td align="left">Hs.1478</td><td align="left">Blood coagulation</td><td align="left">6.69</td><td align="left">14</td></tr><tr><td align="left">SERPINI1</td><td align="left">Hs.78589</td><td align="left">Proteinase inhibitor</td><td align="left">6.68</td><td align="left">6</td></tr><tr><td align="left">SERPINA7</td><td align="left">Hs.76838</td><td align="left">Proteinase inhibitor</td><td align="left">6.60</td><td align="left">7</td></tr><tr><td align="left">GP1b&#x003b1;</td><td align="left">Hs.1472</td><td align="left">Platelet aggregation</td><td align="left">5.68</td><td align="left">6</td></tr><tr><td align="left">PROC</td><td align="left">Hs.2351</td><td align="left">Blood coagulation</td><td align="left">5.63</td><td align="left">6</td></tr><tr><td align="left">Factor 10</td><td align="left">Hs.47913</td><td align="left">Blood coagulation</td><td align="left">4.66</td><td align="left">6</td></tr><tr><td align="left">Factor 2</td><td align="left">Hs.76530</td><td align="left">Blood coagulation</td><td align="left">4.50</td><td align="left">6</td></tr><tr><td align="left">GP 9</td><td align="left">Hs.1144</td><td align="left">Platelet aggregation</td><td align="left">4.02</td><td align="left">6</td></tr><tr><td align="left">Factor 3</td><td align="left">Hs.62192</td><td align="left">Blood coagulation</td><td align="left">3.60</td><td align="left">2</td></tr><tr><td align="left">FGG</td><td align="left">Hs.75431</td><td align="left">Fibrin</td><td align="left">2.60</td><td align="left">3</td></tr><tr><td align="left">SEPPINE1</td><td align="left">Hs.82085</td><td align="left">Anti-Fibrinolysis</td><td align="left">1.75</td><td align="left">9</td></tr><tr><td align="left" colspan="5"><bold>
                              <italic>Signaling Genes:</italic>
                           </bold></td></tr><tr><td align="left">UNC 13</td><td align="left">Hs.155001</td><td align="left">Apoptosis induction</td><td align="left">11.19</td><td align="left">4</td></tr><tr><td align="left">CARD 4</td><td align="left">Hs.19405</td><td align="left">Apoptosis, caspase activator</td><td align="left">10.68</td><td align="left">14</td></tr><tr><td align="left">TNFRSF17</td><td align="left">Hs.2556</td><td align="left">Apoptosis signaling</td><td align="left">10.19</td><td align="left">14</td></tr><tr><td align="left">ARL 1</td><td align="left">Hs.242894</td><td align="left">Cell-cell signaling</td><td align="left">8.66</td><td align="left">2</td></tr><tr><td align="left">LGALS 3</td><td align="left">Hs.79339</td><td align="left">Signaling, scavenger activity</td><td align="left">7.65</td><td align="left">6</td></tr><tr><td align="left">FAT</td><td align="left">Hs.166994</td><td align="left">Tumour suppressor</td><td align="left">7.15</td><td align="left">2</td></tr><tr><td align="left">TNFSF9</td><td align="left">Hs.1524</td><td align="left">Apoptosis signaling</td><td align="left">6.85</td><td align="left">6</td></tr><tr><td align="left">BBC3</td><td align="left">Hs.87246</td><td align="left">Apoptosis signaling</td><td align="left">6.77</td><td align="left">9</td></tr><tr><td align="left">TNFRSF13&#x003b2;</td><td align="left">Hs.158341</td><td align="left">Apoptosis signaling</td><td align="left">6.49</td><td align="left">6</td></tr><tr><td align="left">DDX24</td><td align="left">Hs.155986</td><td align="left">Apoptosis signaling</td><td align="left">6.11</td><td align="left">6</td></tr><tr><td align="left">TNFRSF11&#x003b2;</td><td align="left">Hs.81791</td><td align="left">Apoptosis signaling</td><td align="left">6.11</td><td align="left">7</td></tr><tr><td align="left">TNFRSF10&#x003b2;</td><td align="left">Hs.51233</td><td align="left">Apoptosis signaling</td><td align="left">6.09</td><td align="left">6</td></tr><tr><td align="left">BNIP2</td><td align="left">Hs.155596</td><td align="left">Apoptosis signaling</td><td align="left">5.81</td><td align="left">1</td></tr><tr><td align="left">MGST 2</td><td align="left">Hs.81874</td><td align="left">Cell-cell signaling</td><td align="left">5.50</td><td align="left">6</td></tr><tr><td align="left">CUL 4</td><td align="left">Hs.183874</td><td align="left">Tumour suppressor</td><td align="left">5.35</td><td align="left">6</td></tr><tr><td align="left">BAF 53A</td><td align="left">Hs.274350</td><td align="left">Cell-cell signaling</td><td align="left">5.26</td><td align="left">6</td></tr><tr><td align="left">MAPK 1</td><td align="left">Hs.324473</td><td align="left">Apoptosis induction</td><td align="left">5.11</td><td align="left">14</td></tr><tr><td align="left">CUL 2</td><td align="left">Hs.82919</td><td align="left">Tumour suppressor</td><td align="left">5.09</td><td align="left">6</td></tr><tr><td align="left">P2RX 1</td><td align="left">Hs.41735</td><td align="left">Apoptosis, ion channel activity</td><td align="left">4.43</td><td align="left">6</td></tr><tr><td align="left">TYROBP</td><td align="left">Hs.9963</td><td align="left">Intracellular receptor signaling</td><td align="left">2.51</td><td align="left">13</td></tr><tr><td align="left">CNIH</td><td align="left">Hs.201673</td><td align="left">Intracellular signaling</td><td align="left">2.13</td><td align="left">9</td></tr><tr><td align="left">ADR&#x003b1;1A</td><td align="left">Hs.52931</td><td align="left">Cell-cell signaling</td><td align="left">2.08</td><td align="left">3</td></tr><tr><td align="left">DAPK 1</td><td align="left">Hs.153924</td><td align="left">Apoptosis induction</td><td align="left">2.01</td><td align="left">9</td></tr><tr><td align="left" colspan="5"><bold>
                              <italic>Defense-related Genes:</italic>
                           </bold></td></tr><tr><td align="left">TFF 1</td><td align="left">Hs.350470</td><td align="left">Defense response, maintenance</td><td align="left">7.65</td><td align="left">9</td></tr><tr><td align="left">TFF 3</td><td align="left">Hs.82961</td><td align="left">Extracellular defense response</td><td align="left">6.98</td><td align="left">7</td></tr><tr><td align="left">GAGE 1</td><td align="left">Hs.128231</td><td align="left">Cellular defense response</td><td align="left">6.82</td><td align="left">6</td></tr><tr><td align="left">DEF&#x003b2;3</td><td align="left">Hs.283082</td><td align="left">Extracellular defense response</td><td align="left">6.01</td><td align="left">5</td></tr><tr><td align="left">RU 2</td><td align="left">Hs.61345</td><td align="left">Extracellular defense response</td><td align="left">5.83</td><td align="left">6</td></tr><tr><td align="left">DEF&#x003b1;4</td><td align="left">Hs.2582</td><td align="left">Extracellular defense response</td><td align="left">5.81</td><td align="left">6</td></tr><tr><td align="left" colspan="5"><bold>
                              <italic>Interferons-related Genes:</italic>
                           </bold></td></tr><tr><td align="left">IFN&#x003b1;R1</td><td align="left">Hs.1513</td><td align="left">JAK-STAT cascade, recptor</td><td align="left">5.41</td><td align="left">8</td></tr><tr><td align="left">IRF 7</td><td align="left">Hs.166120</td><td align="left">Transcription regulation</td><td align="left">5.05</td><td align="left">6</td></tr><tr><td align="left">IF 144</td><td align="left">Hs.82316</td><td align="left">Invasive growth response</td><td align="left">2.69</td><td align="left">5</td></tr><tr><td align="left">IRF 6</td><td align="left">Hs.11801</td><td align="left">Transcription regulation</td><td align="left">2.06</td><td align="left">14</td></tr><tr><td align="left">IL 18</td><td align="left">Hs.83077</td><td align="left">Angiogenesis</td><td align="left">1.76</td><td align="left">6</td></tr><tr><td align="left">ISGF3&#x003b3;</td><td align="left">Hs.1706</td><td align="left">Regulatory</td><td align="left">1.28</td><td align="left">9</td></tr><tr><td align="left">IRF 5</td><td align="left">Hs.334450</td><td align="left">Transcription regulation</td><td align="left">1.23</td><td align="left">9</td></tr><tr><td align="left">IFN&#x003b1;R2</td><td align="left">Hs.86958</td><td align="left">Receptor activity</td><td align="left">1.06</td><td align="left">2</td></tr><tr><td align="left">IFN&#x003b3;R1</td><td align="left">Hs.180866</td><td align="left">Receptor activity</td><td align="left">0.80</td><td align="left">5</td></tr><tr><td align="left">IFN&#x003b3;</td><td align="left">Hs.856</td><td align="left">Growth regulation</td><td align="left">0.53</td><td align="left">4</td></tr><tr><td align="left">IRF 3</td><td align="left">Hs.75254</td><td align="left">Transcription regulation</td><td align="left">0.40</td><td align="left">5</td></tr><tr><td align="left">IRF 2</td><td align="left">Hs.83795</td><td align="left">Transcription regulation</td><td align="left">0.32</td><td align="left">4</td></tr><tr><td align="left">IRF 1</td><td align="left">Hs.80645</td><td align="left">Transcription regulation</td><td align="left">0.30</td><td align="left">3</td></tr></tbody></table><table-wrap-foot><p>Order is arranged from the highest to lowest value based on the expression range (log<sub>2</sub>).</p></table-wrap-foot></table-wrap></sec></back></article>



